Research location
Sanlúcar de Barrameda
Andalusia, Spain
Advertisement
Research activity in Sanlúcar de Barrameda
Andalusia, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 15 trials and 15 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Sanlúcar de Barrameda
15 linked trials · page 1 of 1Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart FailureNCT02900378 · 2016-12-20 · 1 site observation
COMPLETED
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation EventNCT02661217 · 2016-02-12 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18 · 1 site observation
COMPLETED
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsNCT02064868 · 2014-01-31 · 1 site observation
TERMINATED
Safety and Tolerability of Initiating LCZ696 in Heart Failure PatientsNCT01922089 · 2013-11-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)NCT01555138 · 2012-02-01 · 1 site observation
COMPLETED
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes PatientsNCT01257451 · 2010-12-01 · 1 site observation
COMPLETED
ALiskiren or Losartan Effects on bioMARKers of Myocardial RemodelingNCT01176032 · 2010-06-01 · 1 site observation
COMPLETED
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart FailureNCT00894387 · 2009-05-01 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Exacerbation StudyNCT00845728 · 2009-03-01 · 1 site observation
COMPLETED
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)NCT00549757 · 2007-10-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.